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Abstract
Background: Exogenous NGF or saline was delivered to the detrusor smooth muscle of female
rats for a two-week period using osmotic mini-pumps. We then determined: (1) bladder function
using conscious cystometry; (2) organization of micturition reflexes using Fos protein expression
in lumbosacral (L5-S1) spinal cord neurons; (3) calcitonin gene-related peptide (CGRP)-
immunoreactivity (IR) in lumbosacral spinal cord segments.
Methods: An osmotic pump infused 0.9% NaCl (n = 6) or NGF (n = 6)(2.5 μg/μl solution; 0.5 μl/
hr) for two weeks into the bladder wall. NGF bladder content was determined by enzyme-linked
immunoassays. Bladder function was assessed with conscious cystometry. Immunohistochemical
and imaging techniques were used to determine the distribution of Fos-IR cells and CGRP
expression in the L5-S1 spinal cord in saline and NGF-treated rats two hours after intravesical
saline distention. Fos expression and CGRP-IR in NGF-treated rats with bladder distention was
compared to that observed in cyclophosphamide (CYP; 75 mg/kg; i.p.) treated rats with bladder
distention.
Results: Two-week infusion of NGF into the bladder wall increased bladder weight, reduced
bladder capacity (60%), reduced the intercontraction interval (60%) and increased the amplitude of
non-voiding contractions. NGF treatment and intravesical saline distention (2 hr) increased
expression of Fos protein in L6-S1 spinal cord and altered the distribution pattern of Fos-IR cells.
CGRP-IR in the lumbosacral spinal cord was also increased after NGF treatment.
Conclusion: These data suggest that NGF infusion into the bladder wall induces bladder
overactivity, can reveal a "nociceptive" Fos expression pattern in the spinal cord in response to a
non-noxious bladder stimulus and increases CGRP-IR in the lumbosacral spinal cord.
Background
The exact contribution of nerve growth factor (NGF) to
bladder function is not known but a correlation between
bladder overactivity and elevated urinary bladder NGF has
been suggested. Experimentally-induced cystitis induces
bladder overactivity and increases bladder NGF protein
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model, increased expression of bladder NGF is associated
with hyperactive voiding [1]. Bladder outlet obstruction is
associated with increased expression of bladder NGF [2-
4]. Intrathecal [5], intravesical delivery of NGF [6] or ade-
novirus-mediated NGF overexpression [7] in the bladder
induces bladder overactivity and bladder afferent cell
hyperexcitability [5,8] in control rats. NGF scavenging
methods [6,9] reduce bladder overactivity in rats with
experimentally induced inflammation. Elevated levels of
neurotrophins are detected in the urine of women with
painful bladder syndrome [10] (PBS)/interstitial cystitis
(IC) or in the urothelium of individuals with neuropathic
bladder [11]. However, a recent study failed to demon-
strate an association between increased urothelium/subu-
rothelium NGF with detrusor overactivity or bladder
sensation [12].
Neurotrophins, through interactions with Trk and/or
p75NTR receptors, may contribute to neurochemical
[13,14], electrophysiological [8] and organizational
[4,15] plasticity of lower urinary tract (LUT) pathways
after cystitis. Neurotrophin/Trk and/or p75NTR interac-
tions could induce long-term changes in cells [4], includ-
ing: (1) mediating neurotransmitter phenotype; (2)
influencing dendrite size and synaptic reorganization; (3)
increasing synaptic efficacy; and (4) controlling innerva-
tion density and target organ function.
In the present study, exogenous NGF or saline was deliv-
ered to the detrusor smooth muscle for a two-week period
using osmotic mini-pumps. We then determined: (1)
bladder function using conscious cystometry; (2) organi-
zation of micturition reflexes using Fos protein expression
in lumbosacral (L5-S1) spinal cord neurons and (3) calci-
tonin-gene related peptide (CGRP) immunoreactivity
(IR) in the lumbosacral spinal cord.
Methods
Female Wistar rats (Charles River Canada) were housed
individually on a 12 hr light/12 hr dark cycle. Protocols
were approved by UVM IACUC (06–014), under the
supervision of Office of Animal Care in accordance with
AAALAC and NIH guidelines.
Animal surgery
An osmotic pump (Alza Corporation) infused 0.9% NaCl
(n = 6) or NGF (n = 6)(2.5 μg/μl solution; 0.5 μl/
hr)(Genentech, Inc.) for two weeks. This NGF concentra-
tion and release rate were previously used in chronic,
intrathecal administration of NGF and resulted in bladder
overactivity and hyperexcitability of bladder afferents [5].
Under general anesthesia, the urinary bladder was
exposed through a lower midline abdominal incision. The
osmotic pump was secured subcutaneously in left upper
quadrant of the abdomen. Biocompatible silicon adhesive
(Kwik Sil, World Precision Instruments) was used to
attach the proximal end of PE10 tubing (Clay Adams Par-
sippany, NJ) to the osmotic pump. The distal end of the
tubing was brought into the abdominal cavity and tun-
neled between the detrusor and bladder adventitia. Two
10-0 nylon sutures secured the tubing in the bladder wall.
(Fig. 1A–C)
Twelve days after pump implantation, PE50 tubing with
the end flared was inserted into the dome of the bladder
and secured with a 6-0 nylon purse string suture. The dis-
tal end of the tubing was sealed, tunneled subcutaneously
and externalized [9].
CYP-treatment
A group of rats (n = 4) treated with CYP (75 mg/kg every
3rd day; i.p.) for ten days had intravesical catheters
implanted as described above on day 8.
Cystometrograms
Forty-eight hours after tube implant, rats were placed
unrestrained in a metabolic cage [9]. The bladder catheter
was connected via a T-tube to a pressure transducer and
microinjection pump. Room temperature saline solution
(0.9%) was infused (10 ml/hr) into the bladder and the
animal urinated into a pan on top of a balance [9]. At least
three reproducible micturition cycles were recorded (Lab-
VIEW, National Instruments) and the following recorded
[9]: filling pressure (FP – pressure at the beginning of
bladder filling), threshold pressure (TP – bladder pressure
immediately prior to micturition), micturition pressure
(MP – the maximal bladder pressure during micturition),
presence or absence of non-voiding bladder contractions
(NVCs – increases in bladder pressure at least 10 cm H2O
without release of urine). The post-void residual (PVR)
was measured by aspirating the urine remaining in the
bladder after the last micturition or draining the bladder
by gravity. Bladder capacity (BC) was calculated as the
sum of voided volume and PVR. Compliance was defined
as the mean rise in intravesical pressure (cm H2O/ml)
measured at 0–20% of capacity.
Euthanasia and tissue handling
Two hours after infusion [15], animals were anesthetized
and killed by intracardiac perfusion with oxygenated
Krebs buffer (pH 7.4) (95% O2, 5% CO2) followed by
4% paraformaldehyde. After perfusion, the spinal cords
were dissected, postfixed, rinsed in phosphate buffered
saline (PBS; 0.1 M NaCl in phosphate buffer, pH 7.4) and
placed in sucrose solutions (10–30%) in 0.1 M PBS for
cryoprotection. Spinal cord segments (L5-S1) were sec-
tioned (40 μm) on a freezing microtome. Spinal cord seg-
ments were identified based upon at least two criteria: (1)
the T13 dorsal root ganglion exits after the last rib and (2)Page 2 of 11
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the fused sacral vertebrae.
Preparation of ELISA samples
Prior to perfusion, the urinary bladder was dissected and
weighed. Individual bladders were solubilized in Tissue
Protein Extraction Reagent (Pierce Biotechnology,
Woburn, MA) with protease inhibitors (Roche Diagnos-
tics GmbH, Germany). Tissue was homogenized and cen-
trifuged (10,000 rpm for 5 min); supernatants were used
for NGF quantification [16]. Total protein was deter-
mined (Pierce). The NGF E-max immunoassay system
(Promega Corp., Madison, WI) demonstrates very low
cross-reactivity with structurally related growth factors.
The NGF standard generated a linear standard curve from
7.8–500 pg/ml (r2 = 0.997, p ≤ 0.001). Absorbance values
of standards and samples were corrected by subtraction of
background value. Samples were diluted to bring the
absorbance values onto the linear portion of the standard
curve. Curve fitting of standards and evaluation of NGF
content of samples was performed using a least squares fit.
c-Fos immunohistochemistry
Spinal cord sections (L5-S1) were incubated for 72 hours
at 4°C with c-Fos antisera (1:5K; Calbiochem, San Diego,
CA) diluted in potassium PBS (KPBS) plus 0.4% Triton X-
100. The antibody was visualized with an avidin-biotin
horseradish peroxidase complex (Vector Laboratories,
Burlingame, CA). Tissue sections were mounted on slides,
dehydrated, cleared in xylene, coverslipped with Per-
mount and examined with brightfield microscopy [15].
Tissue from sham or NGF groups was processed simulta-
neously. Control tests run without antisera or with antis-
era preabsorbed with Fos protein eliminated Fos staining.
Quantification and statistical analysis
The number of cells exhibiting Fos-IR was estimated from
15–20 L5-S1 spinal cord sections (separated by 120 μm)
in [15]: (1) medial dorsal horn (MDH); (2) lateral dorsal
horn (LDH); (3) dorsal commissure (DCM) and (4) lat-
eral laminae V–VII including the sacral parasympathetic
nucleus (SPN) in L6-S1 [15]. Counts of Fos-IR cells are
Intraoperative procedure for tubing implantationFigure 1
Intraoperative procedure for tubing implantation. Intraoperative picture depictingthe insertion of PE10 tubing into the 
urinary bladder wall. Bundles of detrusor muscle are dissected from the urothelium (A). A 4–5 mm length of tubing is inserted 
into the bladder wall (B). Tubing is secured in place by two 10-0 nylon sutures (C). Significant (p ≤ 0.001) increase in total uri-
nary bladder nerve growth factor (NGF; D) as detected with ELISA after two-week exogenous delivery of NGF to bladder 
wall. *, p ≤ 0.001. 'n' = 6 for each group in D.Page 3 of 11
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age change in numbers of cells/section.
CGRP immunohistochemistry
Lumbosacral spinal cord sections adjacent to those used
for Fos staining (above) were used for CGRP immunohis-
tochemistry. Groups of experimental animals were proc-
essed simultaneously to decrease the incidence of
variation in staining and background that can occur
between animals and on different processing days. Spinal
cord sections were processed free-floating as previously
described [14]. Briefly, all sections were incubated over-
night at room temperature with primary antibody (CGRP;
1:1000; Phoenix Pharmaceuticals, Burlingame, CA) in 1%
goat serum and 0.1 M phosphate buffered saline (PBS),
and then washed (3 × 10 min) with 0.1 M PBS, pH 7.4.
The tissues were then incubated with Cy3-conjugated goat
anti-rabbit (Jackson Immunoresearch, West Grove, PA;
1:500) antibody for 2 hours at room temperature. Follow-
ing washing (3 × 10 min with PBS), spinal cord sections
were mounted on gelled (0.5%) slides and coverslipped
with Citifluor (Citifluor Ltd., London). Control sections
incubated in the absence of primary or secondary anti-
body were also processed and evaluated for specificity or
background staining levels. In the absence of primary
antibody, no positive immunostaining was observed.
CGRP-IR semi-quantification
Density of CGRP-IR in specific regions of the spinal cord
was determined with the aid of Meta Morph image analy-
sis software (version 4.5r4; Universal Imaging, Downing-
town, PA) as previously described [17,18]. Fluorescence
images were converted to a gray scale for the purposes of
densitometry. The following regions were analyzed in the
L5-S1 spinal cord from both NGF and saline animals:
LDH(laminae I and II), MDH, DCM, the region of the
SPN (L6-S1), LCP (L6-S1). Of the spinal cord sections
processed for CGRP-IR, random sections were selected for
densitometry and viewed through a video camera attach-
ment to the microscope. The image was converted to pix-
els according to a gray scale that ranges in intensity from
0 (white) and 255 (black). The spinal cord section was
centered in the field and the midline dorsal septum was
located. Then a background level was determined from an
area of the spinal cord that did not exhibit CGRP-IR. A
background value was used to set the threshold between
labeled pixels and background pixels. Illumination inten-
sity was held constant throughout the analysis of NGF and
control animals. A standard sized rectangle was overlaid
on the areas of interest (DH, DCM, LCP, SPN) and the
labeled area within the rectangle was measured. Within
each region, four separate measurements were made and
averaged. Transmittance (t) was calculated as t = (gray
level + 1/256). Optical density (OD) was derived from
OD = -log t. Ten-fifteen sections of each segmental level
(L5-S1) were examined from each animal. NGF and saline
animals that were processed together for CGRP-IR were
analyzed together.
Figure preparation
Digital images with exposure times, brightness and con-
trast held constant, were obtained using a CCD camera
(MagnaFire SP; Optronics; Optical Analysis Corp.,
Nashua, NH) and LG-3 frame grabber attached to an
Olympus microscope. Images were imported into Adobe
Photoshop 7.0 (Adobe Systems Incorporated, San Jose,
CA).
Statistics
Comparisons between the number of Fos-IR spinal neu-
rons, NGF bladder content, optical density measurements
of CGRP-IR and cystometrogram variables were made
using ANOVA. When F ratios exceeded the critical value (p
≤ 0.05), Dunnett's test was used to compare means. All
values are expressed as mean ± S.E.M.
Results
Continuous NGF infusion into the bladder wall for two-
weeks
NGF infusion into the bladder wall by osmotic pump sig-
nificantly increased (p ≤ 0.001; 17-fold) NGF bladder
content (Fig. 1D) and bladder mass (Fig. 2A).
Cystometrograms
During bladder filling and micturition, all animals were
moving freely in the metabolic cage. No difference in
behavior was noted between individual animals or
between the study groups. All animals exhibited normal
patterns of activity and inquisitiveness. No animals exhib-
ited any outward signs of pain or distress. Infusion of NGF
into the bladder wall significantly (p ≤ 0.01) decreased the
intercontraction interval (Fig. 2C, Fig. 3) and reduced
bladder capacity by 60% (Fig. 2B, Fig. 3). Infusion of NGF
into the bladder wall was associated with a significant (p
≤ 0.05) increase in peak micturition pressure but no
changes were observed in filling or threshold pressure
(Fig. 4A). Continuous bladder filling was associated with
non-voiding contractions (NVCs) in four animals in each
group (Fig. 3). However, the amplitude of the NVCs was
significantly (p ≤ 0.01) greater in the NGF infusion group
(Fig. 4B). Inter-animal variability in the frequency of
NVCs was clearly present in animals from both groups.
PVR was negligible in both groups. No change in bladder
compliance was determined for either group.
Fos protein expression induced by saline distention of the 
urinary bladder in saline treated rats
In agreement with previous studies [15,19], intravesical
saline infusion induced the expression of Fos-IR cells in
the L6 (45.0 ± 10.0 Fos-IR cells/section) (Fig. 5, 6A) andPage 4 of 11
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whereas few Fos-IR cells were observed in the L5 spinal
segments (Fig. 6A). Fos-IR cells were observed in specific
regions of the L6-S1 spinal cord (Fig. 5, 6B). The largest
percentage (58 ± 7.5% in L6, 60 ± 6.2% in S1) of Fos-IR
cells were observed in the region of the SPN (Figs. 6B).
Smaller percentages of Fos-IR cells were present in DCM
(25 ± 10.2% in L6, 22 ± 6.6% in S1), MDH (8 ± 5.2% in
L6, 9 ± 2% in S1) and LDH (9 ± 3.7% in L6, 9 ± 1.7% in
S1) (Fig. 6B).
Fos protein expression induced by saline distention of the 
urinary bladder in NGF-treated rats
In rats treated with infusion of NGF into the bladder wall,
continuous intravesical infusion (2 hr) of saline signifi-
cantly (p ≤ 0.005) increased the number of Fos-IR cells
observed in the caudal lumbosacral (L6, 376 ± 33.5 cells/
section; S1, 320 ± 27.2 cells/section) but Fos protein
expression in L5 (12 ± 3.5 cells/section) was not altered
(Fig. 5B, 6A). The topographical distribution of Fos-IR
cells was also altered (Fig. 5B, 6B). In L6, the majority of
Fos-IR cells were distributed in the DCM (68 ± 12.4%)
with smaller percentages in the SPN (27 ± 10.0%), MDH
(2 ± 0.7%) and LDH (3 ± 2.0%) (Fig. 6B). Similarly in S1,
the majority of Fos-IR cells were distributed in the DCM
(52 ± 8.8%) with smaller percentages in the SPN (24 ±
6.8%), MDH (15 ± 5.5%) and LDH (9 ± 5.8%).
Saline distention induced Fos expression in NGF-treated 
rats compared to saline distention induced Fos expression 
in CYP-treated rats
The magnitude of Fos-IR cells and the change in the topo-
graphical distribution of Fos-IR cells after intravesical
saline infusion in NGF-treated animals was similar to that
previously reported [15] for CYP-treated rats with contin-
uous intravesical saline infusion (2 hr). In CYP-treated
rats with intravesical saline distention (2 hr), the majority
of Fos-IR cells in the L6 spinal cord were distributed in the
DCM (55.6 ± 7.7%) with smaller percentages in the SPN
(27.4 ± 8.5%), MDH (14.2 ± 4.6%) and LDH (2.8 ± 1.6%)
(Fig. 5C). The majority of Fos-IR cells in the L6-S1 spinal
cord was distributed in the DCM after intravesical saline
distention in NGF- or CYP-treated rats.
Increased expression of CGRP-IR in lumbosacral spinal 
cord (L6-S1) in NGF-treated rats compared to saline 
treated rats
A number of neuropeptides are present in the somata and
processes of urogenital dorsal root ganglion cells with
CGRP and substance P being the most widely distributed
[20]. In NGF-treated rats undergoing conscious cystome-
try, significant increases in CGRP-IR in L6-S1 spinal cord
regions known to participate in micturition reflexes were
observed (Fig. 7). In the L6 spinal segment, CGRP-IR sig-
nificantly (p ≤ 0.01) increased in the MDH and LDH (Fig.
7A–C). In the S1 spinal segment, CGRP-IR significantly (p
≤ 0.01) increased in the LDH, in the DCM, in the region
of the SPN and LCP, through which bladder afferent fibers
project to the SPN (Fig. 7D–F). No changes in CGRP-IR
were observed in the L5 spinal segment with NGF treat-
ment.
Discussion
Two-week infusion of NGF into the bladder wall resulted
in several novel observations: (1) bladder capacity and
intercontraction interval are reduced (~60%) whereas the
amplitude of NVCs and bladder weight are increased; (2)
Fos protein expression in the L6-S1 spinal cord is
Effects of NGF on cystometry variablesFigure 2
Effects of NGF on cystometry variables. Summary bar 
graphs depict the significant (*, p ≤ 0.01) increase in bladder 
weight (A), decrease in bladder capacity (B), and decrease in 
intercontraction interval (C) in NGF-treated rats. 'n' = 6 for 
each group.Page 5 of 11
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cord is altered in response to intravesical saline distention;
and (3) CGRP-IR is significantly increased in specific
regions of the L6-S1 spinal cord involved in micturition
reflexes. These data suggest that NGF infusion into the
bladder wall induces bladder overactivity and can reveal a
"nociceptive" Fos expression pattern in the spinal cord in
response to a non-noxious bladder stimulus. Although
other studies have examined the effects of exogenous NGF
on bladder function, this study differs from those in sev-
eral areas: (1) the route of exogenous NGF delivery (intra-
muscular compared to intrathecal, intravesical or
adenovirus-mediated) [5-7]; (2) the demonstration of
increased Fos protein and altered Fos distribution induced
by bladder distention in NGF-treated rats; and (3) the
demonstration of increased CGRP-IR in specific regions of
the L6-S1 spinal cord in NGF-treated rats. The present
study demonstrates both induction of bladder overactiv-
ity and altered spinal cord micturition circuitry in
response to exogenous NGF administration.
Neurotrophic factor expression in urinary bladder may
underlie neurochemical [13,14], organizational [4,15]
and electrical [8] property changes of micturition reflexes
after CYP-induced cystitis. The influence of target organ-
neuron interactions in the adult animal has been demon-
strated [2,4,8]. CYP-induced cystitis alters NGF and recep-
tor expression in urinary bladder, dorsal root ganglia and
major pelvic ganglia [16]. NGF scavenging [6,9] reduces
bladder overactivity in rats with bladder inflammation.
PBS/IC is a chronic inflammatory bladder disease syn-
drome characterized by urinary frequency, urgency,
suprapubic and pelvic pain [21,22]. Numerous theories
including; infection, autoimmune disorder, toxic urinary
agents, deficiency in bladder wall lining and neurogenic
causes have been proposed Pain and altered bladder func-
tion in PBS/IC may involve a change in visceral sensation/
bladder sensory physiology. Altered visceral sensations
[21,22] may be mediated by changes in peripheral blad-
der afferent and central pathways such that bladder affer-
ent neurons respond in an exaggerated manner to
normally innocuous stimuli (allodynia). Neurotrophins
(e.g., nerve growth factor) have been implicated in the
peripheral sensitization of nociceptors [23]. Elevated lev-
els of neurotrophins are in urine [10] or in urinary blad-
der [11] of women with PBS/IC. However, a recent study
did not demonstrate an association of increased urothe-
lium/suburothelium NGF with detrusor overactivity [12].
We exogenously delivered NGF into the urinary bladder
of control rats and determined effects on bladder function
and spinal cord organization of the micturition reflex.
Possible sources of NGF and tissues that express TrkA
receptor in the inflamed bladder include the urothelium,
inflammatory cell infiltrates, and detrusor smooth muscle
[4,16]. Acute (30 min) intravesical infusion (20 μg/ml)
[6], or chronic intrathecal (1–2 weeks, 2.5 μg/μl) [5] infu-
sion of NGF induce bladder overactivity. We chose to
infuse NGF into the bladder wall for a two-week period
(2.5 μg/μl) to determine if this route and duration of infu-
sion, used for intrathecal administration [5], could also
induce bladder overactivity. This dose and duration of
NGF delivery produced a NGF bladder content of 15 pg/
μg protein. This NGF level was comparable to those
reported in tissues (bladder, spinal cord) after spinal cord
injury [16] or bladder outlet obstruction [2]. With NGF
treatment in the present study, rats exhibited bladder
overactivity with a reduction in bladder capacity and
Cystometrogram recordingsFigure 3
Cystometrogram recordings. Exogenous delivery of 
NGF (2.5 μg/μl) decreased bladder capacity (increased void-
ing frequency). Continuous cystometrogram recordings in 
saline (A) and NGF-treated rats (B). Arrows point to some 
non-voiding bladder contractions. The x-axis represents the 
time (minutes, min) and the y-axis represents the intravesical 
pressure (cm H2O). The amount of saline voided (ml) is also 
illustrated.Page 6 of 11
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tion interval). Suturing PE tubing directly into the bladder
wall for a focused delivery likely contributed to the
appearance of NVCs in 4/6 animals in both control and
NGF groups. We do not normally observe NVCs in control
rats with implanted intravesical catheters [3,9]. Despite
the appearance of NVCs in both groups, the amplitude of
the NVCs in the NGF-treated group was significantly
greater. We also observed a small, but significant, increase
in peak micturition pressure with NGF treatment but the
reasons for this are not clear. An increase in peak micturi-
tion pressure may result from changes in urethral outlet
resistance resulting in increases in PVR. However, PVR was
negligible in both NGF-treated and control rats. It should
also be noted that NGF levels achieved in the present
study were less than those achieved in the DRG [5] with
intrathecal infusion of NGF at the identical dose and dura-
tion used in the present study. Despite lower NGF tissue
Effects of NGF on cystometry variablesFigure 4
Effects of NGF on cystometry variables. Summary bar 
graphs depict the significant (*, p ≤ 0.05) increase in peak 
micturition pressure (B) and significant (*, p ≤ 0.01) increase 
in amplitude of non-voiding contractions (NVCs)(C) in NGF-
treated rats. No changes in filling pressure (FP) or threshold 
pressure (TP) were observed (B). 'n' = 6 for each group.
Fos induction in NGF-treated ratsigure 5
Fos induction in NGF-treated rats. Brightfield photo-
graphs from sections (40 μm) of the L6 spinal cord showing 
the distribution of Fos-IR cells after intravesical saline disten-
tion (2 hr) in: saline treated rats (A), NGF-treated rats (B), 
or cyclophosphamide (CYP) treated rats (C). MDH, medial 
dorsal horn; LDH, lateral dorsal horn; DCM, dorsal commis-
sure; CC, central canal; SPN, sacral parasympathetic nucleus. 
Calibration bar represents 100 μm.Page 7 of 11
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ity was still observed.
The present study also sought to examine the effect of
exogenous NGF treatment on Fos protein expression
induced by bladder distention to determine if bladder
overactivity was associated with altered (magnitude and
distribution) Fos expression in L6-S1 spinal neurons. NGF
infusion in the bladder wall increased expression of Fos-
IR in spinal neurons and altered the Fos expression pat-
tern in the caudal lumbosacral spinal cord induced by
bladder distention. Intravesical saline distention induces
Fos-IR in spinal neurons located predominantly in the
MDH, LDH and SPN regions of L6-S1 spinal cord of the
control animals [15,19]. The pattern and magnitude of
Fos expression induced by intravesical saline distention is
altered with NGF treatment. Saline or NGF treatment did
not affect threshold or filling pressure and there was a
small, but significant effect on peak micturition pressure.
Thus, it is unlikely that increases in urinary bladder pres-
sure contribute substantially to increased expression of
Fos protein. The altered Fos distribution pattern in NGF-
treated rats with intravesical saline distention resembles
that following noxious irritation (1% acetic acid) [19] of
urinary bladder in control animals and intravesical saline
(non-noxious) bladder distention in CYP-treated rats
[15]. Thus, NGF treatment with intravesical saline disten-
tion can reveal a "nociceptive" Fos expression pattern in
the spinal cord in response to a non-noxious bladder
stimulus. This situation may be analogous to the altered
visceral sensation of PBS/IC patients in which a normally
non-noxious stimulus (bladder filling) is perceived as
painful [21,22]. Altered visceral sensations from the uri-
nary bladder (i.e., pain at low or moderate bladder filling)
that accompany PBS/IC [21,22] may be mediated by
changes in the properties of peripheral bladder afferent
and central pathways such that neurons respond in an
exaggerated manner to normally innocuous stimuli (allo-
dynia).
The present study determined if exogenous NGF treat-
ment could affect the central distribution of the neu-
ropeptide, CGRP, known to be expressed in bladder
afferent cells in the dorsal root ganglia as well as in affer-
ent nerve processes. Several studies have demonstrated
alterations in neuropeptide and neuropeptide receptor
expression in PBS/IC and in animal models of bladder
inflammation. Substance P (SP)-IR [24] and SP receptor
(neurokinin-1) mRNA [25] increases in bladder biopsies
from patients with IC. Rodent models of bladder inflam-
mation using either intravesical mustard oil [26] or intra-
peritoneal injection of cyclophosphamide [14] have
demonstrated increases in CGRP- and SP-IR in bladder
afferent neurons and central projections. The functional
significance of an up-regulation of CGRP in bladder path-
ways following CYP-induced cystitis is not known but
changes in neuropeptide expression and release at both
central and/or peripheral afferent terminals is possible.
Several reports have suggested that neuropeptide-contain-
ing, capsaicin-sensitive bladder afferents may mediate uri-
nary bladder overactivity [27-29]. Botulinum toxin
continues to be explored as a novel treatment for IC/PBS
and sensory urgency [30,31]. Several studies suggest that
improvements in bladder function and reductions in
bladder pain responses are attributable to botulinum
Magnitude and Distribution of Fos in NGF-treated ratsFigure 6
Magnitude and Distribution of Fos in NGF-treated 
rats. Histogram (A) showing the segmental distribution of 
Fos-immunoreactive (IR) cells/section (s) in the rat spinal 
cord (L5-S1) after intravesical saline distention in saline or 
NGF-treated rats. *, p ≤ 0.005. Histogram (B) showing the 
distribution of Fos-IR cells in four regions of the L6 spinal 
cord after intravesical saline distention in saline or NGF-
treated rats. Values represent the percentage of the total 
population of Fos-IR cells induced in each experimental para-
digm. The four regions analyzed include: SPN, sacral para-
sympathetic nucleus; DCM, dorsal commissure; MDH, medial 
dorsal horn; LDH, lateral dorsal horn. #, p ≤ 0.01; *, p ≤ 
0.005. 'n' = 6 for the saline and NGF groups.Page 8 of 11
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CGRP Spinal Cord Expression in NGF-treated ratsFigure 7
CGRP Spinal Cord Expression in NGF-treated rats. CGRP-IR increases in lumbosacral spinal cord with exogenous NGF 
treatment. CGRP-IR in the L6 (A-B) and S1 (D-E) spinal segment in control (A, D) and NGF-treated (B, E) rats. A, D. Fluo-
rescence photographs showing CGRP-IR in the L6 (A) and S1 (D) spinal segment of control (saline) + bladder distention. B, E. 
Fluorescence photographs showing CGRP-IR in the L6 (B) and S1 (E) spinal segment with NGF treatment + bladder disten-
tion. Increased density of CGRP-IR was observed in the medial (MDH) to lateral (LDH) extent of the superficial laminae (I-II) 
of the dorsal horn (DH) with NGF treatment in L6 (C) and S1 (F) segments. Changes in CGRP-IR in other spinal cord regions 
were more dramatic in the S1 spinal segment. Increased CGRP-IR was present in a fiber bundle extending from Lissauer's tract 
in lamina I along the lateral edge of the DH to the region of the sacral parasympathetic nucleus (SPN) (lateral collateral path-
way of Lissauer, LCP) in the S1 segment (F). Although this fiber bundle was present in control tissue sections, the staining was 
less intense (D) and was less frequently observed in transverse sections compared to NGF treatment (E). Faint CGRP-IR was 
present in the region of the SPN in control sections (A, D). With NGF treatment, CGRP-IR in the SPN region also increased 
in the S1 segment. Increased CGRP-IR was also present in the dorsal commissure (DCM) with NGF treatment (D, E, F). Sum-
mary bar graphs of CGRP-IR optical density (O.D.) as measured in specific regions of the L6-S1 spinal cord (C, F). Calibration 
bar represents 125 μm. *, p ≤ 0.01.
BMC Physiology 2007, 7:9 http://www.biomedcentral.com/1472-6793/7/9toxin inhibition of CGRP release from afferent nerve ter-
minals [30,31]. In addition to potential effects of CGRP
on bladder function, changes in neuropeptide expression
and release at central terminals could further result in a
remodeling of spinal cord circuitry controlling micturi-
tion [32]. This remodeling may include changes: (1) in
the synaptic organization of spinal micturition reflexes;
(2) in the neurochemical coding of specific neuronal ele-
ments (primary afferent neurons, interneurons) and (3)
in the organization of ascending and descending projec-
tions to spinal reflexes. In addition to neurochemical
changes in micturition reflex circuitry, changes in the elec-
trical [5,8] properties of neurons involved in micturition
reflexes after bladder inflammation have also been dem-
onstrated. Such changes may also be mediated by altered
expression of neurotrophic factors [5,8] and channel pro-
teins [8] and may underlie bladder functional changes
observed with bladder overactivity.
Conclusion
Exogenous infusion of NGF into the bladder wall reduces
the intercontraction micturition interval, reduces bladder
capacity, increases bladder mass, increases and changes
the Fos protein expression in the L6-S1 spinal cord and
increases CGRP expression in specific regions of the L6-S1
spinal cord. The present study adds further support for the
involvement of urinary bladder NGF in bladder overactiv-
ity and altered central micturition circuitry.
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